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Abstract
We followed 188 euthyroidic persons undergoing treatment for multidrug resistant tuberculosis 
(MDR-TB) in the state of Karnataka, India to determine the incidence of hypothyroidism during 
anti-tuberculosis treatment. Overall, among MDR-TB patients with valid thyroid stimulating 
hormone (TSH) values, about 23% developed hypothyroidism (TSH value ≥10 mIU/ml) during 
anti-tuberculosis treatment; the majority (74%) occurring after 3 months of treatment. Among 133 
patients who received a regimen that contained ethionamide, 42 (32%) developed hypothyroidism. 
Among 17 patients that received a regimen that contained para-aminosalicylate sodium, 6 (35%) 
developed hypothyroidism. Among 9 HIV positive patients on anti-retroviral treatment, 4 (44%) 
developed hypothyroidism. These results differ from previously reported 4% incidence of 
hypothyroidism amongst patients who passively reported thyroidal symptoms during treatment, 
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suggesting routine serologic monitoring of TSH throughout the course of treatment for MDR-TB 
is warranted.
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1. Introduction
Multidrug-resistant tuberculosis (MDR-TB) is defined as tuberculosis (TB) that is resistant 
to isoniazid and rifampicin, the two most efficacious anti-TB drugs [1]. MDR-TB has 
emerged as a major threat to TB control in India with approximately 62,000 new cases 
occurring annually [1] [2]. In Karnataka state, India, Programmatic Management of Drug-
resistant TB (PMDT) started in 2011. All patients with laboratory-confirmed drug-resistant 
TB are treated with a standard regimen; this includes an intensive phase consisting of 
kanamycin, cycloserine, levofloxacin, ethionamide, ethambutol, and pyrazinamide for 6 – 9 
months followed by a continuation phase of 18 months with cycloserine, levofloxacin, 
ethionamide, and ethambutol [2]. In the event of drug intolerance or severe adverse reactions 
to kanamycin and cycloserine, paraaminosalicylate sodium (PAS) may be used as a 
substitute drug [3]. PAS and ethionamide are known to cause hypothyroidism [4]. Anti-
retroviral drugs (stavudine, didanosine, and protease inhibitors) used for treatment of HIV 
can also cause hypothyroidism [5]. According to studies carried out elsewhere, 54% – 69% 
of patients might develop hypothyroidism during treatment for MDR-TB [6]–[8].
Under PMDT, serologic testing for thyroid-stimulating hormone (TSH), a biomarker for 
thyroid functioning, is conducted only amongst MDR-TB patients who passively report 
experiencing signs and symptoms of hypothyroidism. However, because hypothyroidism 
often presents with sub-clinical manifestations that are often masked by other conditions 
(e.g., arthralgia, depression, ectodermal dysplasia, psychosis, and xeroderma), it may be 
underdiagnosed [9]. Thus, we conducted a prospective study to find the proportion of cases 
that develop hypothyroidism during intensive phase of MDR-TB treatment, using routine 
serological TSH testing.
2. Materials and Methods
2.1. Patient Selection
All adult (≥15 years of age) patients registered under PMDT in Karnataka during October, 
2014-March, 2015 were eligible for enrolment. Those not willing to provide written 
informed consent or found suffering from hypothyroidism during pre-treatment evaluation 
were excluded.
2.2. Serological Testing
Serologic TSH levels were obtained at baseline, at end of 3 and 6 months of anti-
tuberculosis treatment using an ultrasensitive sandwich chemi-luminesent-immunologic 
assay at a private laboratory in Bangalore accredited by the College of American Pathologist 
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and National Accreditation Board for Testing Calibration. Hypothyroidism was defined as 
TSH value ≥10 mIU/ml irrespective of clinical symptoms. Patients found suffering from 
hypothyroidism were provided free treatment with levothyroxine according to international 
guidelines [9].
2.3. Data Collection Data Management and Statistical Analysis
Patient characteristics, anti-tuberculosis drugs prescribed, and TSH values were obtained 
from the PMDT register, treatment cards and laboratory reports. Data was recorded in a 
structured data collection sheet, double entered, validated and analysed using EpiData 
software (EpiData Association, Odense, Denmark).
Proportions developing hypothyroidism and 95% confidence intervals (CI) were calculated. 
Chi-square was used to detect differences in proportions that developed hypothyroidism 
(alpha <0.05).
2.4. Ethical Considerations
The study was approved by the Institutional Ethics committees of Rajiv Gandhi Institute of 
TB and Chest Diseases, Bangalore, National Tuberculosis Institute, Bangalore, the Ethics 
Advisory Group, International Union Against Tuberculosis and Lung Disease (The Union), 
and the Division of Global HIV and Tuberculosis, Centers for Disease Control and 
Prevention, Atlanta, GA USA
3. Results
Of 194 persons being treated for MDR-TB, 5 (2.5%) patients did not receive a TSH test at 
baseline, and one was found to be suffering from hypothyroidism during pre-treatment 
evaluation; these patients were excluded from analysis. Of the remaining 188 patients, 165 
(88%) received ethionamide, 5 (3%) received PAS and 18 (10%) both PAS and ethionamide. 
There were 19 patients who were HIV positive, 9 received ART. Excluding those who died 
(n = 7), lost to follow-up (n = 12) and transferred out (n = 1) by the third month, 168 were 
eligible for TSH testing. Of them, 33 were not tested due to for various programmatic 
reasons. At 3 months, 135 (80%) were tested of which 12 developed hypothyroidism. 
Excluding those that had developed hypothyroidism by 3 months, 123 were eligible for TSH 
testing at 6 months. Of them, 8 were not tested. Of 115 tested, 31 additional patients 
developed hypothyroidism between 3 and 6 months. Thus overall, 43 (23%) developed 
hypothyroidism during anti-tuberculosis treatment (95% CI: 17% – 29%).
With the exception of females in the first three months of anti-tuberculosis treatment (17% 
females vs 5% males; p = 0.018), overall risk of developing hypothyroidism was not found 
related to age, sex or medication received (Table 1). It is worth noting, however, that among 
133 patients who received a regimen that contained ethionamide, 42 (32%) developed 
hypothyroidism. Among 17 patients that received a regimen that contained PAS, 6 (35%) 
developed hypothyroidism. Also among 9 HIV positive patients on ART, 4 (44%) developed 
hypothyroidism.
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Among MDR-TB patients with valid TSH values, about 23% developed hypothyroidism 
during antituberculosis treatment, with the majority (74%) occurring after 3 months of 
treatment. These results differ from a report using routine programmatic monitoring data 
(TSH conducted only among symptomatic patients) where 4% developed hypothyroidism 
[10]. These results suggest that serological TSH monitoring may be important throughout 
the course of MDR-TB treatment. All patients should receive serological TSH monitoring 
during MDR-TB treatment to detect subclinical cases of hypothyroidism, which if not 
treated may lead to poor quality of life, and unfavourable outcomes including death and loss 
to follow-up. Findings of this study could have application to all patients treated under 
PMDT in India. A limitation of the present study was that TSH testing was performed only 
at the third and sixth months of treatment. It is likely that testing at more regular intervals 
and throughout the entire length of MDR-TB treatment would increase the time to detection 
of hypothyroidism. Future studies are needed to find out the proportion of MDR-TB patients 
developing hypothyroidism during continuous phase as well, as susceptibility for 
hypothyroidism may continue beyond IP. A substantial number of patients (11%) either died 
or were lost to follow-up. It is possible that some these patients may have suffered from 
hypothyroidism, thus underestimating incidence.
5. Conclusion
Undiagnosed hypothyroidism has serious potential sequelae to MDR-TB patients and 
increases the risk for additional physical and mental health problems. The current PMDT 
policy of waiting for thyroidal symptoms to develop may underestimate the true burden and 
put patients at unnecessary risk and worsen clinical outcomes. Routine TSH testing should 
be considered for all patients receiving anti-tuberculosis treatment for MDR tuberculosis, 
especially those receiving regimens containing PAS and ethionamide or antiretrovirals.
Acknowledgments
The study was undertaken as a part of the “TB Operations Research Training Project” conducted by The 
International Union against TB and Lung Disease (The Union) with funding support from The Global Fund through 
Project Axshya. This training project was conceived and implemented by The Union (South-East Asia Regional 
Office, New Delhi, India) in collaboration with Central TB Division (Directorate General of Health Services, 
Ministry of Health and Family Welfare, Government of India), the National TB Institute (Directorate General of 
Health Services, Ministry of Health and Family Welfare, Government of India Bangalore, India), World Health 
Organization (India Country Office), and U.S. Centers for Disease Control and Prevention (Division of Global HIV 
and Tuberculosis).
References
1. World Health Organization. Global Tuberculosis Report, 2014 (Drug-Resistant TB, Surveillance and 
Response). World Health Organization; Geneva, Switzerland: 2015. [WHO/HTM/TB/2015.07]
2. Central Tuberculosis Division, Directorate General of Health Services. Revised National 
Tuberculosis Control Programme, Guidelines on programmatic management of drug-resistant 
tuberculosis (PMDT) in India. 2012. Available at: https://www.medbox.org/guidelines-on-
programmatic-management-of-drug-resistant-tb-pmdt-in-india-1/preview
3. Macgregor AE, Somner AR. The Anti-Thyroid Action of Para-Aminosalicylic Acid. The Lancet. 
1954; 264:931–936. http://dx.doi.org/10.1016/S0140-6736(54)92552-0. 
Munivenkatappa et al. Page 4













4. Drucker D, Eggo MC, Salit IE, Burrow GN. Ethionamide-Induced Goitrous Hypothyroidism. 
Annals of Internal Medicine. 1984; 100:837–839. http://dx.doi.org/10.7326/0003-4819-100-6-837. 
[PubMed: 6721300] 
5. Silva GA, Andrade MC, Suguide A, et al. Association between Antiretrovirals and Thyroid 
Diseases: Across-Sectional Study. Archives of Endocrinology and Metabolism. 2015; 59:116–122. 
http://dx.doi.org/10.1590/2359-3997000000023. [PubMed: 25993673] 
6. Modongo C, Zetola NM. Prevalence of Hypothyroidism among MDR-TB Patients in Botswana. 
International Journal of Tuberculosis and Lung Diseases. 2012; 16:1561–1562. http://dx.doi.org/
10.5588/ijtld.12.0403. 
7. Satti H, Mafukidze A, Jooste PL, et al. High Rate of Hypothyroidism among Patients Treated for 
MDR-TB in Lesotho. International Journal of Tuberculosis and Lung Diseases. 2012; 16:468–472. 
http://dx.doi.org/10.5588/ijtld.11.0615. 
8. Andries A, Isaakidis P, Das M, et al. High Rate of Hypothyroidism in Multi-drug-Resistant 
Tuberculosis Patients Co-Infected with HIV in Mumbai, India. PloS One. 2013; 10:e78313. http://
dx.doi.org/10.1371/journal.pone.0078313. [PubMed: 24194919] 
9. Garber JR, Cobin RH, Gharib H, et al. Clinical Practice Guidelines for Hypothyroidism in Adults: 
Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid 
Association. Thyroid. 2012; 22:1200–1235. http://dx.doi.org/10.1089/thy.2012.0205. [PubMed: 
22954017] 
10. Akshata JS, Swapna R, Chakraboty A, Somashekar M. Hypothyroidism in MDR-TB Treatment—
Rare Occurrence, but a Major Concern. Egyptian Journal of Chest Diseases and Tuberculosis. 
2015; 64:671–674. http://dx.doi.org/10.1016/j.ejcdt.2015.03.022. 
Munivenkatappa et al. Page 5

















































































































































































































































































































































































































































































































































































































































































































J Tuberc Res. Author manuscript; available in PMC 2016 September 01.
